Nair, Prajeeda M.
Rendo, Matthew J.
Reddoch-Cardenas, Kristin M.
Burris, Jason K.
Meledeo, Michael A.
Cap, Andrew P.
2020-08-07T14:54:29Z
2020-08-07T14:54:29Z
2020
0037-1963
https://doi.org/10.1053/j.seminhematol.2020.07.006
http://hdl.handle.net/20.500.12010/11745
Hematologic diseases include a broad range of acquired and congenital disorders, spanning
dysfunction of the bone marrow, red blood cells, leukocytes and platelets. The plasma proteins of the
coagulation system, the complement system as well as the immunoglobins can also be affected. Finally,
hematologic diseases affect the vascular endothelium from which blood arises during embryogenesis, and
with which blood constantly interacts.
Unsurprisingly, a common component of treatment strategies for patients with hematologic disease
involves replacement or enrichment of missing, dysfunctional or consumed constituents of blood through
transfusion. This review will focus on the recent advances in the use of plasma and its derivatives,
cryoprecipitate, immunoglobin preparations and individual clotting factors for patients with acquired and
congenital hematologic disorders.
31 páginas
image/jepg
Seminars in Hematology
reponame:Expeditio Repositorio Institucional UJTL
instname:Universidad de Bogotá Jorge Tadeo Lozano
Plasma
Hematologic disease
Transfusion
COVID-19
Recent advances in use of fresh frozen plasma, cryoprecipitate, immunoglobulins and clotting factors for transfusion support in patients with hematologic disease
Artículo
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
info:eu-repo/semantics/embargoedAccess
info:eu-repo/semantics/acceptedVersion
Acceso restringido
https://doi.org/10.1053/j.seminhematol.2020.07.006